Journal: Journal of the Chinese Medical Association : JCMA

Article Title: Elevated serum levels of T-cell immunoglobulin and mucin-domain containing molecule 3 in patients with systemic inflammation following COVID-19 vaccination

doi: 10.1097/JCMA.0000000000000969

Figure Lengend Snippet: Cytokines array in two patients with postvaccine inflammatory syndrome and two healthy subjects. The immune profiles were investigated using a human XL cytokine Proteome Profiler array (ARY022b; R&D Systems). Patient samples were obtained before glucocorticoid treatment. TIM-3, BAFF, uPAR, Resistin, PDGF-AB/BB, MIP-3β, and I-TAC (thick bracket***) in patients (P1, P2) were two-fold higher than in the two healthy subjects (N1, N2) who received ChAdOx1 nCoV-19 vaccine. BAFF = B-cell activating factor; BDNF = brain-derived neurotrophic factor; CD = cluster of differentiation; CXCL = chemokine (C-X-C motif) ligand; Dkk-1 = dickkopf-1; FGF = fibroblast growth factor; FLT 3 ligand = Fms-like tyrosine kinase receptor 3 ligand; HGF = hepatocyte growth factor (scatter factor); ICAM-1 = intercellular adhesion molecule 1; I-TAC = interferon-inducible T-cell alpha chemoattractant; IL = interleukin; LIF = leukemia inhibitory factor; MCP = monocyte chemoattractant protein; M-CSF = macrophage colony-stimulating factor; MIC-1 = macrophage inhibitory cytokine 1; MIF = macrophage migration inhibitory factor; MIP-3β = macrophage inflammatory protein-3-beta; MMP-9 = matrix metallopeptidase 9; PAI-1 = plasminogen activator inhibitor-1; PDGF = platelet-derived growth factor; PSA = prostate-specific antigen; RAGE = receptor for advanced glycation endproducts; RBP-4 = retinol-binding protein 4; SHBG = sex hormone-binding globulin; ST2 = interleukin 1 receptor-like 1(IL1RL1); TDGF 1 = teratocarcinoma-derived growth factor 1; TFF3 = trefoil factor 3; TGF-alpha = transforming growth factor–α; TIM-3 = T cell immunoglobulin and mucin-domain containing-3; uPAR = urokinase plasminogen activator surface receptor; VCAM-1 = vascular cell adhesion protein 1; VEGF = vascular endothelial growth factor.

Article Snippet: The immune profile from our patients and healthy controls were measured using a human XL cytokine Proteome Profiler array (ARY022b, R&D Systems).

Techniques: Derivative Assay, Migration, Binding Assay

Journal: American Journal of Cancer Research

Article Title: Tolypothrix Dichloromethane Ethylacetate fraction (TDEF) inhibits cisplatin resistance H357 cell through PI3K/AKT/beta-catenin pathway

doi: 10.62347/JTNQ4812

Figure Lengend Snippet: A. Oral cancer cell line H357 sensitive and H357cisR was seeded on 6 well plates and treated with different concentrations 5, 10, and 15 ug mL-1. With respect to time, the cell morphology changes and becomes rounded in shape, and at higher concentration cell starts to detach from the surface. B. H357CisR cells were treated with indicated dose of TDEF for 48 hrs after which cell death was determined by annexin V/7AAD assay using flow cytometer. The dot plots represent the percentage of early apoptotic (lower right) and late apoptotic cells (upper right). C. Bar diagrams indicate the percentage of cell death; black color portion indicates percentage of early apoptosis and grey color indicates percentage of late apoptosis occur with respective treated groups. D. TDEF treated H357cisR cell pellet was fixed with 70% ethanol and stained with propidium iodide and the cell distribution in different cell cycle phases was analyzed by FACS. Cell cycle arrest was shown highest at 10 ug mL-1 but the cell with the higher concentration of extract has experience apoptosis and necrosis. The percentage of the G1 population was found to be 65.1%, and the control G1 cell population was 47.8%.

Article Snippet: Protein array analysis Human apoptosis array analysis was performed using a proteome profiler apoptotic array kit (ARY009; R & D system.

Techniques: Concentration Assay, Flow Cytometry, Staining, Control

Journal: American Journal of Cancer Research

Article Title: Tolypothrix Dichloromethane Ethylacetate fraction (TDEF) inhibits cisplatin resistance H357 cell through PI3K/AKT/beta-catenin pathway

doi: 10.62347/JTNQ4812

Figure Lengend Snippet: A. The Pp53 and P21 signalling pathways are strongly activated by TDEF treatment. The human apoptosis proteome profiler array used a protein extract (400 µg). The intensities of each array spot were visualized and further quantified using an image. B. The graph shows the relative fold change of proteins with significant differences upon TDEF treatment, setting 1 for control (no treatment of TDEF). Protein levels with higher than ± 2 folds are considered candidates for TDEF-induced cell death.

Article Snippet: Protein array analysis Human apoptosis array analysis was performed using a proteome profiler apoptotic array kit (ARY009; R & D system.

Techniques: Control

Journal: PLoS ONE

Article Title: Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy

doi: 10.1371/journal.pone.0180297

Figure Lengend Snippet: A, Bazedoxifene inhibits tube formation. HUVECs were seeded on Matrigel-coated wells with VEGF (10 ng/ml) in the absence or in the presence of Bazedoxifene and incubated for 24 hours to form a capillary network. The total number of branched tubes was then counted and representative image of capillary network formation was taken. B, Bazedoxifene downregulates several angiogenic factors in vitro . The proteome profiler antibody angiogenesis array was performed. The relative level of selected angiogenesis-related proteins was determined in parallel between untreated (left) and treated (right) HUVEC cells. C, Bazedoxifene inhibits endothelial cellular invasion. HUVECs (1 × 10 6 cells/ml) were added to transwell chamber coated with Matrigel and treated with VEGF (20 ng/ml) in the absence or in presence of Bazedoxifene. After 24 hours, the number of invaded cells was counted, and results are expressed as percentage of invasion (basal invasion with no treatment). D, Bazedoxifene blocks rhabdomyosarcoma cells invasion. Parental RH30 and RH28 cells were starved in 0% FBS medium for 24 hours. After that, cells were seeded (5 × 10 4 cells/well) to the top chamber, and 10% FBS was added into the lower chamber. Cells were treated with Bazedoxifene for 24 hours, and then invasion cells were detected in the bottom chamber using a Cultrex BME Cell Invasion Assay. Statistical analysis of three independent experiments was shown as means, *, P < 0.05.

Article Snippet: Proteome profiler antibody based Angiogenesis array (R & D systems; Cat. No. ARY007) was used according to manufacturer’s instructions to detect the relative levels of expression of angiogenesis related proteins in control and Bazedoxifene treated cells.

Techniques: Incubation, In Vitro, Invasion Assay